Albireo Pharma, Inc. (NASDAQ:ALBO) Q3 2019 Earnings Conference Call - Final Transcript
Nov 06, 2019 • 10:00 am ET
Greetings and welcome to the Albireo Pharma Inc. Third Quarter 2019 Earnings Call. [Operator Instructions]
It is now my pleasure to introduce your host Paul Arndt with LifeScience Advisors. Thank you Mr. Arndt. You may begin.
Paul J. Arndt
Thank you Operator and good morning everyone. Thank you for joining today's call. This morning Albireo issued a press release highlighting its recent business accomplishments and reporting its financial results for the third quarter ended September 30 2019. This press release is accessible via the company's website at www.albireopharma.com. Before proceeding we would like to note that management's comments today may include forward-looking statements regarding the company's plans and expectations. These statements are being made under the Private Securities Litigation Reform Act of 1995 and they are subject to various risks and uncertainties.
Actual results may differ materially due to various important factors including those described in the Risk Factors section of our most recent Form 10-K and our subsequent SEC filings. These filings can be accessed from the Media and Investor section of our website albireopharma.com or on the SEC's website. Any forward-looking statements represent our views as of today Wednesday November 6 2019 and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation to publicly update these statements.
And now I'll turn the call over to Ron Cooper Albireo's President and CEO. Ron?
Thank you Paul and thanks to all of you who have joined us on this morning's conference call. With me today is Albireo's Chief Medical Officer Dr. Pat Horn; our Chief Commercial Officer Pamela Stephenson and our Chief Financial Officer Simon Harford. We're pleased to the opportunity to update you on the meaningful progress we've made in recent months in the development of the Vics about our proprietary le about acid or iMac inhibitor. We believe this product candidate holds the potential to be a compelling treatment option for a wide range of pediatric homeostatic Liberty diseases. Our lead indication is progressive familial interest, Paddick Kohli's thesis for FIFA. And we plan to study motivation that in other colas, static diseases. Now for those of you that are new to Albert rail, there are multiple types of pieces all caused by genetic mutations that can result in bile acid buildup in the liver. We estimate that P could affect about 8000 to 10,000 patients across the spectrum disease in the US and in Europe.
Patients tend to be diagnosed early in life often at the ages of 1 or 2 and they can quickly progress to cirrhosis liver failure and death if untreated. They also experience a variety of symptoms with pruritis which is an intense insatiable itch tend to be the the most troublesome for both the patients and their families. There are no medications approved to treat PFIG. Treatment options are limited to invasive surgical procedures such as biliary diversion surgery or a permanent stoma bag that's used to drain bile acids or liver transplant. Our ultimate goal is